On April 2024, Korean Biomedical Review reported that Celltrion won the Denmark national tender for its subcutaneous infliximab formulation, Remsima SC®. Remsima SC® (infliximab) will be supplied in Denmark for one year by Celltrion’s Danish subsidiary. This subsidiary is planning to expand its marketing team and initiate marketing activities to increase the prescription rate of the product.
This comes after Celltrion’s successful bids for the supply of Remsima SC® (infliximab) in the Netherlands and Norway earlier this year.